OncoTherapy Science,Inc.
TSE Growth
¥23.00
+4.55%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of 0.1.
- Current assets comfortably cover current liabilities (current ratio 13.59).
!Watch-points
- Thin interest cover: operating profit covers interest only about -618.1 times.
- Return on equity is on the lower side at -44%.
- Return on capital employed is on the lower side at -37%.
- The company reported a net loss in the latest period.
- Sales growth has been slow over five years (about -23% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-16.55
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
2 / 4
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 4 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap¥94億
Current Price¥ 23.00
High / Low¥ 34.00 / 18.00
Stock P/E-8.30
Book Value¥ 5.40
Dividend Yield0%
ROCE-37.01%
ROE-43.98%
Debt to Equity0.10
Current Ratio13.59
P/B Ratio3.9993045
EPS¥ -2.77
PAT Margin-34533.11%
ICR-618.14
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity